Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Post-ASCO 2025 Lung Cancer Highlights
Featuring presentations & discussions on selected lung cancer abstracts from the 2025 American Society of Clinical Oncology (ASCO) annual meeting.
Chair: Noemí Reguart | Moderators: Stephen Liu, Nicolas Girard
Session 1: Optimizing immunotherapy strategies in NSCLC
Overall survival with neoadjuvant nivolumab (NIVO) + chemotherapy (chemo) in patients with resectable NSCLC in CheckMate 816
Patrick Forde Trinity St. James's Cancer Institute, Dublin, Ireland
TROPION-Lung02: Datopotamab deruxtecan (Dato-DXd) plus pembrolizumab (pembro) with or without platinum chemotherapy (Pt-CT) as first-line (1L) therapy for advanced non-small cell lung cancer (aNSCLC)
Luis Paz-Ares 12 October University Hospital, Madrid, Spain
Panel discussion
Session 2: Novel approaches to target EGFR- and HER2-mutated NSCLC
Sacituzumab tirumotecan (sac-TMT) in patients (pts) with previously treated advanced EGFR-mutated non-small cell lung cancer (NSCLC): Results from the randomized OptiTROP-Lung03 study
Li Zhang Sun Yat-sen University Cancer Center, Guangzhou, China
SOHO-01: Safety and efficacy of BAY 2927088 in patients with advanced HER2-mutant non-small cell lung cancer (NSCLC) who were pretreated but naïve to HER2-targeted therapy or had not received any treatment for advanced disease
Herbert Loong The Chinese University of Hong Kong, Hong Kong, China
Panel discussion
Session 3: Emerging treatment approaches in SCLC
Randomized phase II trial investigating whether atezolizumab after chemoradiotherapy (CRT) prolongs survival in limited stage (LS) small cell lung cancer (SCLC)
Bjorn Henning Gronberg Norwegian University of Science and Technology, Norway
Lurbinectedin (lurbi) + atezolizumab (atezo) as first-line (1L) maintenance treatment (tx) in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC): Primary results of the phase 3 IMforte trial
Luis Paz-Ares 12 October University Hospital, Madrid, Spain
Panel discussion
